Drug-induced isolated visceral angioneurotic edema

Internal Medicine

Volumn 44, Issue 9, 2005, Pages 975-978

  Arakawa, Masahiro ^a   Murata, Yaeko ^a   Rikimaru, Yuya ^a   Sasaki, Yasuhiko ^a  

^a JAPANESE RED CROSS SOCIETY   (Japan)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Lisinopril; Valsartan

Indexed keywords

LISINOPRIL; QUINAPRIL; VALSARTAN;

ABDOMINAL PAIN; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; ASCITES; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; JEJUNUM DISEASE; KIDNEY GRAFT REJECTION; LAPAROSCOPIC SURGERY; MAINTENANCE THERAPY; SMALL INTESTINE DISEASE; SYMPTOM;

ADULT; ANGIONEUROTIC EDEMA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; LISINOPRIL; RENAL DIALYSIS; TETRAZOLES; VALINE;

EID: 27844554843     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.975     Document Type: Article

References (14)

1. Schmidt TD, McGrath KM. Angiotensin-converting enzyme inhibitor angioedema of the intestine: A case report and review of the literature. Am J Med Sci 324: 106-108, 2002.
2. Yeung JH, Coleman JW, Park BK. Drug-protein conjugates - IX. Immunogenicity of captoril-protein conjugates. Biochem Pharmacol 34: 4005-4012, 1985.
3. Basran GS, Morley J, Paul W, Turner-Warwick M. Evidence in man of synergistic interaction between putative mediators of acute inflammation and asthma. Lancet 24: 935-937, 1982.
4. Ohsawa I, Satomura A, Fake Y, et al. Worsening fluid retention in a patient with hereditary angioedema and end-stage renal disease. Intern Med 43: 708-712, 2004.
5. Oudit G, Girgrah N, Allard J. ACE inhibitor-induced angioedema of the intestine: Case report, incidence, pathophysiology, diagnosis and management. Can J Gastroenterol 15: 827-832, 2001.
6. Sica DA, Gehr TW. The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease. J Renin Angiotensin Aldosterone Syst 3: 247-254, 2002.
7. Mchaourab A, Sarantopoulos C, Stowe DF. Airway obstruction due to late-onset angioneurotic edema from angiotensin-converting enzyme inhibition. Can J Anaesth 46: 975-978, 1999.
8. Soo Hoo GW, Dao HT, Klaustermeyer WB. Severe angioedema and respiratory distress associated with lisinopril use. West J Med 158: 412-417, 1993.
9. Kelly JG, Doyle GD, Carmody M, Glover DR, Cooper WD. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. Br J Clin Pharmacol 26: 781-786, 1988.
10. Blum RA, Olson SC, Kohli RK, Horvath AM, Sedman Al, Posvar EL. Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients on chronic hemodialysis. J Clin Pharmacol 30: 938-942, 1990.
11. Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinctics of valsartan in patients with liver disease. Clin Pharmacol Ther 62: 272-278, 1997.
12. Oates JA, Wilkinson GR. Principles of drug therapy. In: Harrison's Principles of Internal Medicine. 13th ed. Isselbacher KJ, Braunwald E, Wilson JD, et al, Eds. McGraw-Hill, New York, 1994: 399-400.
13. DeVane CL. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol Bull 36: 5-21, 2002.
14. Crawford JM, Cotran RS. Ectopic pancreas. In: Robin's Pathologic Basis of Disease. 6th ed. Cotran RS, Kumar V, Collins T, Eds. WB Saunders Company, Philadelphia, 1999: 904.